Method Sign up free

Borrower record · Q2 2026

Arrowhead Pharmaceuticals

As filed by 2 BDCs · period end 30 June 2026NAICS 31-33 · Manufacturing

Two lenders report $158.7m of Arrowhead Pharmaceuticals at Q2 2026, marked at 113.4 cents. Every filed tranche is fixed-rate: no filer disclosed a spread or an index on any of them.

Filed fair value
$158.7m
2 funded positions
Reporting lenders
2
across 2 filed positions
Aggregate mark
113.4c
cost filed on all 2 positions
Maturities to
2031
one date, 1 August 2031
Periods on record
5
Q2 2025 → Q2 2026

How this total is counted

Capital structure

First-Lien Senior Secured, on all 2 positions whose seniority a filer disclosed.

Rate structure

Fixed, on all 2 positions whose interest type a filer disclosed.

Maturity profile

all 2 funded positions dated
2031
$158.7m

5.1 years to maturity, weighted by fair value across the 2 dated positions.

Filed over time

5 periods · aggregate only

Filed fair value

$165.5m
Q2 2025
$175.5m
Q3 2025
$157.4m
Q4 2025
$156.7m
Q1 2026
$158.7m
Q2 2026

Aggregate marknot to zero

116.4c
Q2 2025
118.9c
Q3 2025
112.8c
Q4 2025
111.0c
Q1 2026
113.4c
Q2 2026

Q2 2025, Q3 2025, Q4 2025, Q1 2026, Q2 2026 — every filer reporting the borrower at each period, aggregated. No lender is separated out at any period.

Credit flags

No lender reports this borrower on non-accrual, and no filed tranche pays in kind.

Not in the filings

Sign up for free

Who holds it, and where they mark it.

2 lenders hold the same credit and mark it differently. Behind the gate, one row each — for this borrower and for every other one on this site, free and with no limit on how many you read.

LenderPositionsFair valueMarkSpreadMaturityAccrual

Every filing behind this page

2 filers · Q2 2026
FilerCIKFormPeriodFiledAccession
Sixth Street Lending Partners000192530910-Q2026-06-302026-08-050001193125-26-335004
Sixth Street Specialty Lending, Inc. (TSLX)000150865510-Q2026-06-302026-08-040001193125-26-332725

Related borrowers

Same lenders

Same sector